New York, NY—August 2, 2005
The Federal Drug Administration (FDA) has approved the Cox-2 inhibitor Celebrex for use in treating a form of arthritis in the spine called ankylosing spondylitis. The disease affects more than 400,000 Americans, typically between the ages of 17 and 35, Pfizer said in a statement. Ankylosing spondylitis can also cause inflammation, pain and stiffness in the shoulders, knees, hips, ribs and feet.
Whether patients are recovering from joint replacement surgery or sports injuries, or suffering from arthritis, osteoarthritis or lupus, they are looking to their healthcare practitioners to help them put this data into perspective and help them make the right treatment decisions.
The following Hospital for Special Surgery doctors are available to comment on ankylosing spondylitis and treatments, including options other than Celebrex:
Theodore R. Fields, MD, FACP
Associate Attending Physician
Available to discuss: Medication alternatives to COX-2 inhibitors, non-medication approaches to arthritis, the COX-2 selective vs non-selective anti-inflammatory agents.
Joseph A. Markenson, MD
Available to discuss: Current drug studies involving patients with rheumatic disease (rheumatoid arthritis, osteoarthritis, and lupus), medication alternatives to COX-2s, reasons for withdrawal of Vioxx®, non-medication approaches to arthritis, the COX-2 selective vs non-selective anti-inflammatory agents.
Linda A. Russell, MD
Assistant Attending Physician
Available to discuss: rheumatic disease and orthopedic pharmacology, osteoporosis treatment, systemic lupus erythematosus, rheumatoid arthritis, gout, soft tissue rheumatism
Anne R. Bass, MD
Assistant Attending Physician
Available to discuss: systemic lupus erythematosus, rheumatoid arthritis, gout, soft tissue rheumatism, lyme disease, vasculitis, inflammatory eye disease
For a discussion of how to reduce the side effects of COX-2 inhibitors - the group of drugs in which Vioxx® and Celebrex® belong - please visit:
For information on the Vioxx® withdrawal and its implications for the management of osteoarthritis for patients, please visit:
About Hospital for Special Surgery
Hospital for Special Surgery (HSS) is the world’s leading academic medical center focused on musculoskeletal health. HSS is nationally ranked No. 1 in orthopedics and No. 3 in rheumatology by U.S. News & World Report (2017-2018), and is the first hospital in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center four consecutive times. HSS has one of the lowest infection rates in the country. HSS is an affiliate of Weill Cornell Medical College and as such all Hospital for Special Surgery medical staff are faculty of Weill Cornell. The hospital's research division is internationally recognized as a leader in the investigation of musculoskeletal and autoimmune diseases. HSS has locations in New York, New Jersey and Connecticut.